

Final Agenda
35th meeting of the Committee for Risk Assessment

24 November - 4 December 2015

ECHA Conference Centre (Annankatu 18, Helsinki)

24 November starts at 9.00
27 November breaks at 13.00
1 December resumes at 14:00
4 December ends at 13.00

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

RAC/A/35/2015
For adoption

Item 3 – Declarations of conflicts of interest to the Agenda

Item 4 – Report from other ECHA bodies and activities

- a) Report on RAC 35 action points, written procedures and update on other ECHA bodies

RAC/35/2015/01
RAC/35/2015/02
(room document)

For information

- b) RAC workplan for all processes

For information

- c) General RAC procedures

For information

Item 5 – Requests under Article 77 (3)(c)

No requests.

Item 6 – Requests under Article 95 (3)

- a) 1-methyl-2-pyrrolidone (NMP)

For information

Item 7 – Harmonised classification and labelling (CLH)

7.1 CLH dossiers

A. Hazard classes for agreement without plenary debate (fast-track)

- Medetomidine (human health hazards): skin and eye corrosion/irritation, respiratory /skin sensitisation, mutagenicity and carcinogenicity
- Penthiopyrad (ISO): aquatic acute toxicity, aquatic chronic toxicity; all human health hazards (=no classification) except carcinogenicity and developmental toxicity
- Clethodim (ISO): physical hazards, acute toxicity, STOT SE, serious eye damage / eye irritation, respiratory / skin sensitisation, mutagenicity, carcinogenicity, environmental hazards
- 2,3-epoxypropyl methacrylate: acute toxicity (oral and inhalation routes), serious eye damage, eye corrosion, skin sensitisation
- hexaflumuron (ISO): physical hazards, acute toxicity (dermal route), skin damage /eye irritation, skin sensitisation, environmental hazards
- 3,3'dicyclohexyl-1,1'methylenebis(4,1-phenylene)diurea: environmental hazards

B. Hazard classes for agreement with plenary debate

- a) anthraquinone
- b) cadmium carbonate
- c) cadmium dihydroxide
- d) cadmium dinitrate
- e) 2,3-epoxypropyl methacrylate
- f) 3,3'dicyclohexyl-1,1'methylenebis(4,1-phenylene)diurea
- g) silver zinc zeolite
- h) hexaflumuron (ISO)
- i) penthiopyrad (ISO)
- j) nonadecafluorodecanoic acid (PFDA) and its ammonium and sodium salts
- k) triadimenol (ENV hazards)
- ~~l) salicylic acid (developmental toxicity)~~
- m) 4,4'-methylenedimorpholine (MBM) (human health hazards)

- n) Reaction products of paraformaldehyde and 2-hydroxypropylamine (ratio 3:2) (MBO) (toxicity to reproduction)
- o) Reaction product of paraformaldehyde and 2-hydroxypropylamine (ratio 1:1) (HPT) (toxicity to reproduction)
- p) medetomidine (human health hazards)
- q) clethodim (ISO)
- r) Reaction mass of isomers of benzotriazoles and phenols (Tinuvin 171/571)

For discussion and adoption

7.2 Appointment of RAC (co-)rapporteurs for CLH dossiers

RAC/35/2015/03

(restricted room document)

For agreement

Item 8 – Restrictions

8.1 General restriction issues

- a) Revision of the restriction process

RAC/35/2015/04

RAC/35/2015/05

For discussion and agreement

RAC/35/2015/06

(room document)

For information and discussion

8.2 Restriction Annex XV dossiers

- a) Opinion development
 - 1) Methanol – revised draft opinion
 - 2) D4/D5 – revised draft opinion
- b) Conformity check
 - 1) TDFAs

For adoption

For discussion

For agreement

8.3 Appointment of (co-)rapporteurs for restriction dossiers

RAC/35/2015/07

(restricted document)

For agreement

Item 9 – Authorisation

9.1 General authorisation issues

- a) Continuing review of RAC and SEAC recommendations (opinion trees)

RAC/35/2015/08
For discussion and agreement

- b) Update on incoming/future applications for authorisation and on Workshop on streamlining Applications for Authorisation

For information

- c) Amendment of the RAC note "Application for Authorisation: Establishing a reference dose-response relationship for carcinogenicity of hexavalent chromium" to include the intrinsic property "Toxic to reproduction" of the Cr(VI) compounds

RAC/35/2015/09
For discussion and agreement

9.2 Authorisation applications

- a) Outcome of the conformity check and presentation of the key issues

1. One use of chromium trioxide submitted by *Kromatek Oy* on behalf of a group of companies (**Chromium trioxide - Kromatek**):

Use 1: Use of chromium trioxide in Cr(VI) based functional plating

2. Two uses of chromium trioxide submitted by *Grohe AG* (**Chromium trioxide - Grohe**):

Use 1: The use of chromium trioxide for electroplating of different types of substrates with the purpose of creating a long-lasting, high durability surface with a shiny or matte look (also called 'functional plating with decorative character')

Use 2: The use of Chromium Trioxide for pre-treatment step in the electroplating process

- b) First version of the draft opinion:

1. One use of sodium chromate submitted by *Dometic GMBH* and *Dometic Htgépgyártó és Kereskedelmi Zrt.* (**Sodium chromate 1**):

Use 1: The use of sodium chromate as an anticorrosion agent of the carbon steel cooling system in absorption refrigerators up to 0.75% by weight (Cr 6+) in the cooling solution.

2. One use of sodium dichromate submitted by *Boliden Mineral AB* (**Sodium dichromate 1**):

Use 1: The use of sodium dichromate in copper/lead separation in concentrators handling complex sulphide ores.

3. One use of 1,2-dichloroethane submitted by *Laboratoires Expanscience* (**EDC 1**):

Use 1: process and extracting solvent in fine chemical processes

For discussion and agreement

- c) Update on the developments in the draft opinions:

1. Six uses of chromium trioxide submitted by LANXESS Deutschland GmbH on behalf of a group of companies (Chromium trioxide 1):

Use 1: Formulation of mixtures

Use 2: Functional chrome plating

Use 3: Functional chrome plating with decorative character

Use 4: Surface treatment for applications in the aeronautics and aerospace industries, unrelated to Functional chrome plating or Functional plating with decorative character

Use 5: Surface treatment (except ETP) for applications in various industry sectors namely architectural, automotive, metal manufacturing and finishing, and general engineering

Use 6: Passivation of tin-plated steel (ETP)

For information and discussion

9.3 Appointment of (co-)rapporteurs for authorisation applications

RAC/35/2015/10
(restricted room document)

For agreement

Item 10 – AOB

Item 11 – Action points and main conclusions of RAC-35

Table with Conclusions and Action points from RAC-35

For adoption